Compare KLRS & NMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLRS | NMI |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 119.5M |
| IPO Year | N/A | 1995 |
| Metric | KLRS | NMI |
|---|---|---|
| Price | $4.94 | $10.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 82.7K | 31.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $9.62 |
| 52 Week High | $11.88 | $11.18 |
| Indicator | KLRS | NMI |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 56.00 |
| Support Level | $4.35 | $9.85 |
| Resistance Level | $5.38 | $10.88 |
| Average True Range (ATR) | 0.37 | 0.27 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 38.18 | 83.04 |
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.